After an over the counter genetic test: Would you make serious health decisions?

Direct-to-consumer (DTC) genetic tests are advertised as a way to “find out what your DNA says”. Some promise insights into ancestry or disease risks, while others claim to provide information on personality, athletic ability, and child talent. People might be drawn to DTC genetic testing in the hope that it will provide clear cut information about their future health. But interpretation of genetic data is complex and context dependent and DTC genetic tests might report false positive and false negative results. A false positive result indicates that a person has a high genetic risk of a disease or condition when they actually don’t, while a false negative result indicates a person has a low genetic risk of a disease or condition when the person actually does have it.

These uncertainties may arise based on several aspects. A genetic test per se may simply deliver a wrong result for a given gene or a given locus within the genome. First, genetic tests from different sources are rarely compared (cross-validated) at a selection of gene loci for reproducible deliverance of identical test results. Second, the genotype of an individual does not all the time translate into the expected clinical phenotype of the patient. There may exist variations at the level of the molecular phenotype, there may exist an array of confounding factors, the patients may be a compound heterozygote, or the two alleles at the patients genetic locus may undergo transcriptional bursting, just  to name a few. Lastly, while upon epidemiological analysis a correlation between a certain gene and the occurrence of a disease or the risk for a disease might exist in large patients populations, the same may not apply to every single patient individually.

Thus, the genome and its working are immensely complex. No wonder then that experts in the field of (pharma)genomics are warning that results found via third party interpretation services need particular care. This is because the “raw data” that such services interpret will contain errors, and because the databases used to interpret the data may not be up to date. When people receive a “bad news” result from a direct-to-consumer (DTC) genetic test, many may turn to their general practitioner (GP) for advice. However, most worrying in this context is an apparent significant gap in genomic literacy among medical doctors and other health care professionals. Indeed, only 1 in 10 physicians responding to a USA-based survey of 10’000 physicians reported feeling confident in their knowledge of (pharmaco)genomics and its clinical implications; less than 1 in 3 physicians had ever ordered a pharmacogenetic test, and only 1 in 8 physicians had recommended or ordered a test in the previous six months. This may even be more of a problem with direct to consumer (DTC) test concerned with personal or  suggestive of a genetic condition, or test results concerning future health risks such as positive BRCA tests and the prospective risk of developing breast cancer.

In any case, receiving direct to consumer (DTC) genetic test results with seemingly positive or negative test result at a certain genetic locus of interest, which would led a patient, or even a healthy individual, to take action, should led healthy individuals, patients, and treating physicians to have i) the test results confirmed by a second, cross validated test in order to exclude experimental errors, and ii) have an true expert in (pharmaco)genetics and/or genetic counselling looking over and analysing the test results in order to circumvent inappropriate measures to be taken. The example of the American lady cited above should be enough of a warning for everyone involved. According experts are easily reachable both in the US and in Canada.

See here a short sequence on the problem we talk about here:

Print Friendly, PDF & Email

 

 

Tags: , , , , , , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • How genetic variation gives rise to differences in mathematical ability October 22, 2020
    DNA variation in a gene called ROBO1 is associated with early anatomical differences in a brain region that plays a key role in quantity representation, potentially explaining how genetic variability might shape mathematical performance in children, according to a study published October 22nd in the open-access journal PLOS Biology by Michael Skeide of the Max […]
  • High-quality cat genome helps identify novel cause of dwarfism October 22, 2020
    A new and improved cat genome developed by the feline research teams at the University of Missouri and Texas A&M University has already proven to be a valuable tool for feline biomedical research by helping to confirm existing gene variants and new candidate genes underlying diseases in cats. The new findings are published October 22nd […]
  • Multiple sclerosis as the flip side of immune fitness October 22, 2020
    About half of the people with multiple sclerosis have the HLA-DR15 gene variant. A study led by the University of Zurich has now shown how this genetic predisposition contributes to the development of the autoimmune disease multiple sclerosis in combination with environmental factors. The decisive factor is the shaping of a repertoire of immune cells […]
  • Scientists use gene therapy and a novel light-sensing protein to restore vision in mice October 22, 2020
    A newly developed light-sensing protein called the MCO1 opsin restores vision in blind mice when attached to retina bipolar cells using gene therapy. The National Eye Institute, part of the National Institutes of Health, provided a Small Business Innovation Research grant to Nanoscope, LLC for development of MCO1. The company is planning a U.S. clinical […]
  • Diagnostic, therapeutic advance for rare neurodegenerative disorder October 21, 2020
    Mayo Clinic researchers, along with national and global collaborators, have developed a potential test for Machado-Joseph disease, or spinocerebellar ataxia type 3 (SCA3)—a disease that has no cure. They also have clarified the role of a gene target associated with the disease.
Top